Skip to main content

Table 5 Comparative estimates of costs, QALYs, and ICERs: sensitivity analysis excluding non-responder anti-TNF costs past 24 weeks

From: Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

 

Anti-TNF user

Anti-TNF non-user

Increment (user vs non-user)

95% CIa

Canada

 Costs

12,405

1656

10,749

(8868, 12,789)

 QALYs

0.626

0.609

0.017

(−0.008, 0.042)

 ICER

  

626,459

(247,149, Dominated)

France

 Costs

12,566

1696

10,870

(9144, 12,751)

 QALYs

0.620

0.607

0.013

(−0.011, 0.036)

 ICER

  

857,992

(284,242, Dominated)

UK

 Costs

12,973

737

12,236

(8981, 15,769)

 QALYs

0.627

0.606

0.021

(−0.015, 0.059)

 ICER

  

578,899

(187,442, Dominated)

Germany

 Costs

12,321

1682

10,640

−877,112,728

 QALYs

0.642

0.617

0.025

(0.001, 0.050)

 ICER

  

422,568

(206,749, 14,587,057)

Hong Kong

 Costs

11,935

891

11,044

(7243, 15,470)

 QALYs

0.619

0.586

0.033

(−0.011, 0.076)

 ICER

  

335,418

(124,073, Dominated)

  1. aLower bound = 2.5 th, upper bound = 97.5 th percentile of bootstrapped distribution